E-viri
Odprti dostop
-
Signoriello, Elisabetta; Signori, Alessio; Lus, Giacomo; Romano, Giuseppe; Marfia, Girolama Alessandra; Landi, Doriana; Napoli, Francesca; D' Amico, Emanuele; Zanghí, Aurora; Di Filippo, Paola Sofia; Caliendo, Daniele; Carotenuto, Antonio; Spiezia, Antonio Luca; Fantozzi, Roberta; Centonze, Diego; Lucchini, Matteo; Mirabella, Massimiliano; Cocco, Eleonora; Frau, Jessica; Maniscalco, Giorgia Teresa; Di Battista, Maria Elena; Foschi, Matteo; Surcinelli, Andrea; Bonavita, Simona; Abbadessa, Gianmarco; Pasquali, Livia; Di Gregorio, Maria; Ferrò, Maria Teresa; Sormani, Maria Pia; Schiavetti, Irene
Multiple sclerosis and related disorders, 07/2024, Letnik: 87Journal Article
•High-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression.•Ocrelizumab and natalizumab could be the best strategy in naive highly active multiple sclerosis patients.•NEDA-3 after three years of treatment may be achieved in a high percentage of patients starting treatment with NAT or OCR. in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in highly active MS patients (HAMS). Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NEDA-3 achievement in treatment-naïve HAMS patients receiving NAT or OCR over three years. we retrospectively enrolled treatment-naïve HAMS patients undergoing NAT or OCR, collecting demographic, clinical, and instrumental data before and after treatment initiation to compare with propensity score analysis disease activity, time to disability worsening, and NEDA-3 achievement. we recruited 281 HAMS patients with a mean age of 32.7 years (SD 10.33), treated with NAT (157) or OCR (124). After three years, the Kaplan-Meier probability of achieving NEDA-3 was 66.0 % (95 % CI: 57.3 % - 76.0 %) with OCR and 68.2 % (95 % CI: 59.9 % - 77.7 %) with NAT without significant differences between the two groups (p = 0.27) starting HE DMT with monoclonal antibodies for HAMS could achieve NEDA-3 in a high percentage of patients without differences between NAT or OCR.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.